人干扰素阴道泡腾片联合匹多莫德治疗宫颈HPV感染的临床效果

Abstract
Figure/Table
References
Related Citation (13)

Download: PDF (1257 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid in the treatment of persistent cervical high-risk type human papilloma virus (HPV).Methods A total of 211 cases with persistent cervical high-risk type HPV infection diagnosed in the Third Medical Center of PLA General Hospital were collected from January 2019 to December 2020, and they were randomly divided into two groups according to treatment options. The experimental group of 109 cases were treated with human interferon a2b vaginal effervescent tablets combined with pidotimod oral liquid, while the control group of 102 cases were treated with human interferon a2b vaginal effervescent tablets as single-agent therapy. The outcomes of cervical high-risk HPV at 6 months and 12 months after treatment were compared between the two groups.Results The effective rate (all negative conversion rate) of HPV was 51.38% (56/109) in the experimental group and 23.53% (24/102) in the control group after 6 months’ treatment, and there was a significant difference between the two groups (P<0.05).The effective rate of HPV was 73.39% (80/109) in the experimental group and 42.16% (43/102) in the control group after 12 months’ treatment, and there was a significant difference between the two groups (P<0.05). Further analysis of HPV typing remaining positive in the experimental group and the control group was conducted, and the effective rate of the top three types (HPV16/18, HPV52 and HPV58) after treatment in the experimental group was better than that in the control group.Conclusion Human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid can effectively improve the negative conversion rate of cervical high-risk type HPV, and more effective for removal of cervical HPV16/18 infection, which provides a reference for clinical treatment of HPV persistent infection.

Key words： cervical high-risk human papilloma virus outcome of HPV immunotherapy human interferon pidotimod

Received: 01 January 2022

ZTFLH:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Zhenzhen
	LI Weiping
	ZHANG Xiaoli
	CHEN Di
	TONG Jun

Cite this article:

GAO Zhenzhen,LI Weiping,ZHANG Xiaoli等. Clinical efficacy of human interferon vaginal effervescent tablets combined with pidotimod in treatment of cervical HPV infection[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2022, 33(7): 556-559.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2022/V33/I7/556

[1]	Lortet T J,Georges D,Bray F,et al.Profiling global cancer incidence and mortality by socioeconomic development[J].Int J Cancer,2020,147(11):3029-3036.
[2]	郭思洁,田黎黎,孔琪,等.武昌区域单中心人乳头瘤病毒感染及不同基因型的分布特征[J].中国实用妇科与产科杂志,2019,35(1):123-126.
[3]	Harper D M,Franco E L,Wheeler C,et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a fandomised controlled trial[J].Lancet,2004,364(9447):1757-1765.
[4]	张一萍,星丽娜,张云鹤.治疗性人类乳头瘤病毒疫苗研究进展[J].武警医学,2021,32(10):901-906.
[5]	于筱卿,赵瑾,王国庆.干扰素联合重组人干扰素α-2b凝胶对HPV持续阳性的效果观察[J].中国生化药物杂志,2016,36(1):98-100.
[6]	陈光,张黎.消疣汤结合干扰素α-2b凝胶治疗高危型人乳头瘤病毒感染宫颈病变疗效观察[J].现代中西医结合杂志,2019,28(23):2563-2565.
[7]	Hou S,Yuan L,Jin P,et al.A clinical study of the effects of lead poisoning on the intelligence and neurobehavioral abilities of children[J]. Theor Biol Med Model,2013,10:13.
[8]	李春琳,张红平,王应海,等.hTERT基因多态性与宫颈癌前病变关联性研究[J].中华肿瘤防治杂志,2019,26(18):1323-1328.
[9]	王登海,陈忠萍,居峰,等.TCT联合HPV-DNA及端粒酶检测在宫颈癌前病变评估中的应用价值[J].检验医学与临床,2017,14(21):3193-3194.
[10]	WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention[OL].[2021-07-07]https://www.who.int/publications/i/ite m/9789240030824.
[11]	吴月利,陆仲女,王聪平.妇科门诊患者宫颈癌筛查认知程度及其影响因素[J].武警医学,2020,31(6):479-482.
[12]	周雅轩.免疫促进剂匹多莫德的临床应用进展[J].天津药学,2018,30( 5):58-61.
[13]	Zhang L,Bi Q, Deng H,et al. Human papilloma virus infection among women with cervical lesions and cervical cancer in eastern China:genotype-specific prevalence and attribution[J]. BMC Infect Dis, 2017,17(1):107.
[14]	宋磊,付晓宇.多型别人乳头瘤病毒感染与宫颈癌[J].中国计划生育和妇产科,2016,8(10):12-14.
[15]	宋建东,宋静慧,于聪祥,等.影响宫颈病变患者HPV转归的多因素分析[J].中国实用妇科与产科杂志,2018,34(8):892-897.
[16]	王秀芳,赵辉.人乳头瘤病毒感染和阴道微生态状况对宫颈鳞状上皮内病变的影响[J].中华医院感染学杂志,2021,31(2):268-271.